Patient-reported outcomes in a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel (axi-cel) versus standard of care therapy in patients with relapsed/refractory large b-cell lymphoma (ZUMA-7)
Elsawy, M. Chavez, J. C. Avivi, I. Larouche, J. F. Wannesson, L. Cwynarski, K. Osman, K. Davison, K. Rudzki, J. D. Dahiya, S.
Elsawy, M.
Chavez, J. C.
Avivi, I.
Larouche, J. F.
Wannesson, L.
Cwynarski, K.
Osman, K.
Davison, K.
Rudzki, J. D.
Dahiya, S.
Citations
Altmetric:
Abstract
Authors
Elsawy, M.
Chavez, J. C.
Avivi, I.
Larouche, J. F.
Wannesson, L.
Cwynarski, K.
Osman, K.
Davison, K.
Rudzki, J. D.
Dahiya, S.
Dorritie, K.
Jaglowski, S.
Radford, John A
Morschhauser, F.
Cunningham, D.
Garcia-Sancho, A. M.
Tzachanis, D.
Ulrickson, M. L.
Karmali, R.
Kekre, N.
Thieblemont, C.
Enblad, G.
Dreger, P.
Malladi, R.
Joshi, N.
Wang, W. J.
Solem, C. T.
Snider, J. T.
To, C.
Kersten, M. J.
Chavez, J. C.
Avivi, I.
Larouche, J. F.
Wannesson, L.
Cwynarski, K.
Osman, K.
Davison, K.
Rudzki, J. D.
Dahiya, S.
Dorritie, K.
Jaglowski, S.
Radford, John A
Morschhauser, F.
Cunningham, D.
Garcia-Sancho, A. M.
Tzachanis, D.
Ulrickson, M. L.
Karmali, R.
Kekre, N.
Thieblemont, C.
Enblad, G.
Dreger, P.
Malladi, R.
Joshi, N.
Wang, W. J.
Solem, C. T.
Snider, J. T.
To, C.
Kersten, M. J.
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, et al. Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). Blood. 2021 Nov;138. PubMed PMID: WOS:000736398801204.